These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30822530)

  • 21. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
    Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
    Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm.
    Canal-Sotelo J; Trujillano-Cabello J; Larkin P; Arraràs-Torrelles N; González-Rubió R; Rocaspana-Garcia M; Barallat-Gimeno E
    BMC Palliat Care; 2018 May; 17(1):81. PubMed ID: 29807537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
    Lux EA; Schwittay A; Kleeberg UR; Papke J
    MMW Fortschr Med; 2018 Jul; 160(Suppl 4):18-23. PubMed ID: 29974433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
    Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
    Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating breakthrough pain in oncology.
    Mercadante S
    Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
    Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
    Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Episodic Cancer Pain: Patient Reporting, Prevalence, and Clinicodemographic Associations at Initial Cancer Pain Clinic Assessment.
    Reis-Pina P; Acharya A; Barbosa A; Lawlor PG
    Pain Res Manag; 2020; 2020():6190862. PubMed ID: 32566062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP).
    Camps Herrero C; Reina Zoilo JJ; Monge Martín D; Caballero Martínez F; Guillem Porta V; Aranda Aguilar E; Carrato Mena A; Díaz-Rubio García E; García-Foncillas López J; Feijóo Saus M; López López R
    Clin Transl Oncol; 2019 Mar; 21(3):380-390. PubMed ID: 30094793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription.
    Villegas Estévez F; López Alarcón MD; Alonso Babarro A; Olay Gayoso L; de Castro J; Lería-Gelabert M; Melogno-Klinkas M
    Curr Med Res Opin; 2020 Aug; 36(8):1383-1391. PubMed ID: 32453602
    [No Abstract]   [Full Text] [Related]  

  • 33. Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain.
    Tagami K; Okizaki A; Miura T; Watanabe YS; Matsumoto Y; Morita T; Fujimori M; Kinoshita H
    J Palliat Med; 2018 Nov; 21(11):1636-1640. PubMed ID: 29975582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interference with daily functioning by breakthrough pain in patients with cancer.
    Kang JH; Koh SJ; Oh SY; Kim RB; Shin SH; Lee YG; Kim BS; Ryoo HM; Yoon SY; Jang JS; Oh HS; Choi YJ; Lee MH; Lee KH
    Support Care Cancer; 2020 Nov; 28(11):5177-5183. PubMed ID: 32056013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines.
    Davies AN; Elsner F; Filbet MJ; Porta-Sales J; Ripamonti C; Santini D; Webber K
    BMJ Support Palliat Care; 2018 Sep; 8(3):241-249. PubMed ID: 29875184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
    Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
    J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
    Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
    PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breakthrough cancer pain: The importance of the right treatment at the right time.
    O'Hagan P; Mercadante S
    Eur J Pain; 2018 Aug; 22(7):1362-1374. PubMed ID: 29635732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.